ClinConnect ClinConnect Logo
Search / Trial NCT03238885

Predicting Pathological Complete Response of Rectal Cancer With Magnetic Resonance(MR) Radiomics

Launched by SUN YING-SHI · Aug 1, 2017

Trial Information

Current as of April 25, 2025

Completed

Keywords

ClinConnect Summary

We propose to develop and validate a radiomics model for individualized pCR evaluation after CRT in patients with LARC. We plan to use both pre- and post-CRT MRI data to construct the predictive radiomics model for evaluating if LARC patients achieve pCR after CRT. The ultimate aim is to select appropriate LARC patients for omission of surgery.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • pathologically proved rectal cancer
  • locally advanced rectal cancer (≥T3 or N+)
  • a distance less than 12cm between the lower edge of tumor and the anal margin
  • no evidence of distant metastases
  • no prior anti-cancer therapy before treatment
  • scheduled to receive preoperative CRT
  • Exclusion Criteria:
  • history or concurrent of other malignancy
  • incomplete preoperative CRT
  • failed to receive surgery or unavailable pCR assessment
  • poor quality of MR images for measurement
  • patient quit

About Sun Ying Shi

Sun Ying-Shi is a dedicated clinical trial sponsor specializing in innovative research and development within the pharmaceutical and biotechnology sectors. Committed to advancing healthcare solutions, Sun Ying-Shi focuses on conducting rigorous clinical trials that adhere to the highest ethical and regulatory standards. With a team of experienced professionals, the organization emphasizes collaboration and transparency, ensuring that the safety and well-being of participants are prioritized throughout the research process. Through its comprehensive approach, Sun Ying-Shi aims to bring groundbreaking therapies to market, ultimately improving patient outcomes and enhancing the quality of life for individuals worldwide.

Locations

Beijing, Beijing, China

Patients applied

0 patients applied

Trial Officials

Ying-Shi Sun

Study Chair

Peking University Cancer Hospital & Institute

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials